|
Survival in a Randomized Phase III Trial in Patients with LD Small Cell Lung Cancer Vaccinated with Adjuvant BEC2 and BCG Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Survival in a Randomized Phase III Trial in Patients with LD Small Cell Lung Cancer Vaccinated with Adjuvant BEC2 and BCG conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Survival in a Randomized Phase III Trial in Patients with LD Small Cell Lung Cancer Vaccinated with Adjuvant BEC2 and BCG Clinical research trials and Survival in a Randomized Phase III Trial in Patients with LD Small Cell Lung Cancer Vaccinated with Adjuvant BEC2 and BCG health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Survival in a Randomized Phase III Trial in Patients with LD Small Cell Lung Cancer Vaccinated with Adjuvant BEC2 and BCG. Survival in a Randomized Phase III Trial in Patients with LD Small Cell Lung Cancer Vaccinated with Adjuvant BEC2 and BCG Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Survival in a Randomized Phase III Trial in Patients with LD Small Cell Lung Cancer Vaccinated with Adjuvant BEC2 and BCG clinical trial. Test subjects typically receive the most expert healthcare available for their Survival in a Randomized Phase III Trial in Patients with LD Small Cell Lung Cancer Vaccinated with Adjuvant BEC2 and BCG condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Survival in a Randomized Phase III Trial in Patients with LD Small Cell Lung Cancer Vaccinated with Adjuvant BEC2 and BCG  Survival in a Randomized Phase III Trial in Patients with LD Small Cell Lung Cancer Vaccinated with Adjuvant BEC2 and BCG
Survival in a Randomized Phase III Trial in Patients with LD Small Cell Lung Cancer Vaccinated with Adjuvant BEC2 and BCG
For Condition: Carcinoma, Small Cell Lung
Status: No longer recruiting
Sponsor(s): European Organization for Research and Treatment of Cancer , ImClone Systems,Merck KGaA
Synopsis: This trial is designed to test the impact of adjuvant BEC2 (2.5 mg)/BCG vaccination on survival in patients with LD SCLC. Patients will be stratified by institution, KPS (60 - 70% vs 80 - 100%), and response to first line combined modality therapy (CR vs PR) that consisted of at least a 2 drug regimen (4 - 6 cycles) and a chest radiotherapy regimen. Patients will be randomized to one of two treatment arms: standard arm (Observational cohort) or best supportive care, or the treatment arm (5 intradermal vaccinations of BEC2 (2.5 mg) + BCG given on day 1 of weeks 0, 2, 4, 6, and 10.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Placebo Control, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - 1)Histo-cytologically proven SCLC - 2)Limited disease at diagnosis - 3)Age greater than or equal to 18 - 4)Patients with a clinical response of CR or PR to first line combined modality therapy - 5)KPS greater than or equal to 60 - 6)Adequate bone marrow, liver and heart functions - 7)Written informed Consent Exclusion Criteria: - 1)Prior surgical treatment for SCLC - 2)History of tuberculosis - 3)NCIC CTG grade 3 local skin toxicity reaction (ulceration) to > IU PPD test > 5 IU - 4)HIV positive - 5)Splenectomy or spleen radiation therapy in medical history - 6)Prior therapy to proteins of murine origin - 7)Any second line therapy for SCLC Investigational agent or immune therapy within 4 weeks prior to study randomization - 8)Severe active infections - 9)Active infections requiring systemic antibiotics, antiviral, or antifungal treatments - 10)Serious unstable chronic illness - 11)The use of systemic anti-histamines, NSAID or systemic corticosteroids - 12)Any previous malignancy except adequately treated CIS of the cervix or non melanoma skin cancer or if previous malignancy was more than 5 years prior and there are no signs of recurrence - 13)Pregnancy or breast feeding or absence of adequate contraception for fertile patients - Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed with the patient before randomization in the trial.
Total Enrollment: 500
Location and Contact Information:
Additional Information:
Study ID Numbers: SILVA EORTC 08971;
Study Start Date: September 1998
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00037713
Other Carcinoma, Small Cell Lung Studies:
1. Survival in a Randomized Phase III Trial in Patients with LD Small Cell Lung Cancer Vaccinated with Adjuvant BEC2 and BCG
Related Studies:
Other Carcinoma, Small Cell Lung Clinical Trials
Other Clinical Trials
Other Clinical Trials
Survival in a Randomized Phase III Trial in Patients with LD Small Cell Lung Cancer Vaccinated with Adjuvant BEC2 and BCG
|
|
|
|
|
|
|
|
